No Data
No Data
Honz Pharmaceutical: Half-year report for the year 2024.
Honz Pharmaceutical: Summary of Half-Year Report in 2024.
Honz Pharmaceutical (300086.SZ): Net loss of 0.101 billion yuan in the first half of the year, turning into a loss compared to the same period last year.
Gelonghui August 26th | Honz Pharmaceutical (300086.SZ) announced its interim report for the first half of 2024, with revenue of 0.22 billion yuan, a year-on-year decrease of 33.88%; net income attributable to shareholders of the listed company was -0.101 billion yuan, a year-on-year loss from profit; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.105 billion yuan; basic earnings per share was -0.2241 yuan.
Honz Pharmaceutical (300086.SZ) has appointed Han Dingfu as the Chief Financial Officer.
Honz Pharmaceutical (300086.SZ) announced that the board of directors has agreed to appoint Han Dingfu as the company's chief financial officer, with a term starting from...
Little Excitement Around Honz Pharmaceutical Co., Ltd.'s (SZSE:300086) Revenues As Shares Take 27% Pounding
Kangzhi Pharmaceutical (300086.SZ) announced first-quarter results, with a net loss of 46.5 million yuan, which changed from profit to loss over the previous year
Kangzhi Pharmaceutical (300086.SZ) disclosed its report for the first quarter of 2024. The company achieved revenue of 1.0 during the reporting period...
No Data